Arzneiwerk AG VIDA (FRA:TLIK) Piotroski F-Score: 3 (As of Aug. 31, 2026) — 40% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TLIK Arzneiwerk AG VIDA FRA:TLIK
40 GF Score
Price €0.21
! 7 Warning Signs
View Full Analysis

What is Arzneiwerk AG VIDA Piotroski F-Score?

Arzneiwerk AG VIDA FRA:TLIK +0.98% 40 Piotroski F-Score is 3 as of Aug. 31, 2026, which is 40% below its 10-year median of 5.00. GuruFocus rates FRA:TLIK with a GF Score™ of 40/100. The stock has 7 warning signs investors should review. Among 113 Medical Distribution companies, Arzneiwerk AG VIDA ranks worse than 83.19% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Arzneiwerk AG VIDA has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Arzneiwerk AG VIDA's Piotroski F-Score or its related term are showing as below:

FRA:TLIK' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 7
Current: 3

During the past 13 years, the highest Piotroski F-Score of Arzneiwerk AG VIDA was 7. The lowest was 2. And the median was 5.

Arzneiwerk AG VIDA  (FRA:TLIK) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Arzneiwerk AG VIDA Piotroski F-Score Related Terms


Arzneiwerk AG VIDA Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Arzneiwerk AG VIDA's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arzneiwerk AG VIDA Piotroski F-Score Chart

Arzneiwerk AG VIDA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 5.00 4.00 5.00 5.00

Arzneiwerk AG VIDA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 6.00 5.00 3.00

FRA:TLIK vs MCK, COR, CAH: Piotroski F-Score Comparison

For the Medical Distribution subindustry, Arzneiwerk AG VIDA's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arzneiwerk AG VIDA Piotroski F-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Arzneiwerk AG VIDA's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Arzneiwerk AG VIDA's Piotroski F-Score falls into.


FRA:TLIK
40GF Score
Arzneiwerk AG VIDA FRA:TLIK
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -0.303 + -0.174 + 0.093 + -0.076 = €-0.46 Mil.
Cash Flow from Operations was -0.19 + -0.171 + -0.124 + -0.107 = €-0.59 Mil.
Revenue was 0.028 + -0.001 + 0.001 + 0 = €0.03 Mil.
Gross Profit was 0.028 + -0.001 + 0.001 + 0 = €0.03 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(4.289 + 4.486 + 4.607 + 4.516 + 4.568) / 5 = €4.4932 Mil.
Total Assets at the begining of this year (Mar25) was €4.29 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.
Total Current Assets was €0.04 Mil.
Total Current Liabilities was €2.71 Mil.
Net Income was -0.375 + -0.272 + -0.123 + -0.18 = €-0.95 Mil.

Revenue was 14.517 + 14.796 + 0.031 + 0.04 = €29.38 Mil.
Gross Profit was 0.772 + 0.927 + 0.031 + 0.04 = €1.77 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(12.31 + 12.459 + 12.148 + 4.168 + 4.289) / 5 = €9.0748 Mil.
Total Assets at the begining of last year (Mar24) was €12.31 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.
Total Current Assets was €0.21 Mil.
Total Current Liabilities was €2.57 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Arzneiwerk AG VIDA's current Net Income (TTM) was -0.46. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Arzneiwerk AG VIDA's current Cash Flow from Operations (TTM) was -0.59. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-0.46/4.289
=-0.10725111

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-0.95/12.31
=-0.07717303

Arzneiwerk AG VIDA's return on assets of this year was -0.10725111. Arzneiwerk AG VIDA's return on assets of last year was -0.07717303. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Arzneiwerk AG VIDA's current Net Income (TTM) was -0.46. Arzneiwerk AG VIDA's current Cash Flow from Operations (TTM) was -0.59. ==> -0.59 <= -0.46 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0/4.4932
=0

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/9.0748
=0

Arzneiwerk AG VIDA's gearing of this year was 0. Arzneiwerk AG VIDA's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=0.043/2.706
=0.01589061

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=0.209/2.57
=0.08132296

Arzneiwerk AG VIDA's current ratio of this year was 0.01589061. Arzneiwerk AG VIDA's current ratio of last year was 0.08132296. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Arzneiwerk AG VIDA's number of shares in issue this year was 6.233. Arzneiwerk AG VIDA's number of shares in issue last year was 6.233. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.028/0.028
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1.77/29.384
=0.06023686

Arzneiwerk AG VIDA's gross margin of this year was 1. Arzneiwerk AG VIDA's gross margin of last year was 0.06023686. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=0.028/4.289
=0.00652833

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=29.384/12.31
=2.38700244

Arzneiwerk AG VIDA's asset turnover of this year was 0.00652833. Arzneiwerk AG VIDA's asset turnover of last year was 2.38700244. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+1+0+1+1+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Arzneiwerk AG VIDA has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Arzneiwerk AG VIDA (FRA:TLIK) has a Piotroski F-Score of 3 as of Aug. 31, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Arzneiwerk AG VIDA and its competitors. This is 40% below median its historical median of 5.00. Over the past decade, Arzneiwerk AG VIDA's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Arzneiwerk AG VIDA ranks #94 out of 113 companies in the Medical Distribution industry, placing it in the top 83.2%.
Is Arzneiwerk AG VIDA's Piotroski F-Score too high?
Arzneiwerk AG VIDA's current Piotroski F-Score of 3 is 40% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Medical Distribution industry median Piotroski F-Score is 5.00. Arzneiwerk AG VIDA's value of 3 is 40% below this industry median. Based on the distribution chart, Arzneiwerk AG VIDA ranks #94 out of 113 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Arzneiwerk AG VIDA has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Arzneiwerk AG VIDA's Piotroski F-Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Arzneiwerk AG VIDA ranks #94 out of 113 companies for Piotroski F-Score. This places Arzneiwerk AG VIDA in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Arzneiwerk AG VIDA's value of 3 is 40% below this benchmark. Historically, Arzneiwerk AG VIDA's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Arzneiwerk AG VIDA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Distribution company?
The median Piotroski F-Score among Medical Distribution companies is 5.00, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arzneiwerk AG VIDA's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Arzneiwerk AG VIDA and its competitors. For the Medical Distribution industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arzneiwerk AG VIDA's current Piotroski F-Score is 3, which is 40% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arzneiwerk AG VIDA stock overvalued right now?
Arzneiwerk AG VIDA (FRA:TLIK) has a current Piotroski F-Score of 3. The current Piotroski F-Score is 3, which is 40% below median its 10-year median of 5.00 and 40% below the Medical Distribution industry median of 5.00. Arzneiwerk AG VIDA's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Arzneiwerk AG VIDA (FRA:TLIK), the current Piotroski F-Score is 3 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arzneiwerk AG VIDA Business Description

Other Exchanges TLIK:Germany
Address Ordensmeisterstrasse 15-16, Berlin, DEU, 12099
Arzneiwerk AG VIDA is active in the pharmaceutical industry. The Pharma segment combines pharmaceutical supply with a focus on digitalization and process optimization along the pharmaceutical value chains and the management of large data volumes in the pharmaceutical industry. The company focuses on the growth area of specialty pharma in Germany and Europe.
40GF Score

Get the complete analysis for FRA:TLIK

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.21
Price